NCT00756912终止1 期
A Phase I, Open-Label, Dose Escalation Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Eisai Inc.
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Safety and assessments will be done daily.
研究概览
简要总结
This is a study designed to assess the safety of administration of up to 3 dose levels of eritoran in subjects undergoing or scheduled to undergo allogeneic bone marrow transplant (BMT). An allogeneic BMT is the transplantation of blood stem cells taken from the bone marrow or blood of another person.
详细描述
Please note: in the original protocol, the study phase is listed as "Phase Ib", although the Official Title reads "Phase I".
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet all of the inclusion criteria outlined below in order to be eligible to participate in this study:
- •Adult subjects (aged 18 to 55 years old) undergoing or scheduled to undergo myeloablative conditioning and allogeneic BMT, or stem cells from matched donors.
- •Subjects using either busulfan or total body irradiation (TBI) containing regimens for BMT for the treatment of malignant and nonmalignant diseases. For example:
- •Cyclophosphamide and Total Body Irradiation (CY-TBI) with a TBI dose of at least 1200 cGy of fractionated TBI
- •Etoposide and Total Body Irradiation (VP16-TBI) with a TBI dose of at least 1200 cGy of fractionated TBI
- •Busulfan and cyclophosphamide (BU-CY) with at least 14 mg/kg busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL at steady state.
- •Leukemia patients with:
- •acute myelogenous leukemia (AML)
- •acute lymphoblastic leukemia (ALL) in first or subsequent complete remission
- •chronic myelogenous leukemia (CML) in first or subsequent chronic phase or in accelerated phase
- •myelodysplastic syndrome (MDS) patients.
- •Subjects with non-Hodgkin's lymphoma who are in complete remission as determined by physical exam, CT and PET scans, and are otherwise considered candidates for allogeneic BMT as judged by the treating institution
- •Available matched related CD34+ stem cells (target cell dose between 2 x 10^6/kg and 10 x 10^6/kg (actual body weight)) for transplantation (matched at 6/6 HLA at Class I HLA-A and B and Class II HLA-DRBI).
- •Sex distribution: men or nonpregnant women. Women of childbearing potential must have a negative serum β-human chorionic gonadotropin (hCG) or urine assay prior to eritoran treatment or prior to the beginning of conditioning treatment. Menopausal women must have been amenorrheic for at least 12 months.
- •Has signed informed consent before any study-specific procedures are performed.
排除标准
- •Unwilling or unable to agree to be fully evaluated for all follow-up visits. The subject or subject's representative and the study staff should agree to perform all study assessments even if the subject is discharged from the hospital.
- •Seropositive for human immunodeficiency virus (HIV); testing is not needed if already performed (documentation required) as part of screening for conditioning treatment.
- •Subjects with a documented or possible systemic infection, or suspected of having a medically significant viral, bacterial, or fungal infection at the beginning of treatment on Day -
- •Have taken any investigational medications (ie, not approved by the FDA for any indication) within the 30-day period prior to enrollment into the study.
- •Karnofsky Performance Status (KPS) <60%.
- •Have previously received a bone marrow or stem cell transplant.
- •Are to receive T-cell depleted BMT or stem cell infusions.
- •Are pregnant or lactating.
- •Known sensitivity to eritoran or its excipients.
- •Prior malignancies treated with a curative intent of < 5 years will not be allowed. Previously treated cancer with a curative intent of > 5 years will be allowed.
- •Legal incapacity.
- •Any of the following laboratory parameters within 2 days prior to the beginning of treatment on Day -3:
- •direct bilirubin ≥ 2x ULN
- •liver function tests (ALT or AST) with values ≥ 3x ULN
- •serum creatinine ≥ 2x ULN
- •Subjects who are enrolled in other interventional, investigational protocols. As aGvHD is likely to only occur after treatment with eritoran is completed, investigational treatments for Grades III and IV aGvHD may be allowed and should be discussed with the Sponsor.
- •Subjects with a history of or with current pulmonary disease with forced vital capacity (FVC) or forced expiratory volume in 1 second (FEV1) < 60% predicted (corrected for hemoglobin).
- •Subjects with a history of a cardiac ejection fraction < 45%, or with marked screening or baseline prolongation QT/QTc interval (QTc interval > 470 mSec).
研究组 & 干预措施
1
Experimental
干预措施: E5564 (Drug)
结局指标
主要结局
Safety and assessments will be done daily.
时间窗: Performed daily through Day 28, with follow-up every other week to Day 100 and at 1 year post-transplant.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
早期 1 期
The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's DiseaseHuntington DiseaseNCT06024265ExoRNA Bioscience10
已完成
1 期
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant TumorsAdvanced MalignanciesNCT04353830Innovent Biologics (Suzhou) Co. Ltd.34
招募中
1 期
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant TumorsAdvanced MalignanciesNCT04085185Innovent Biologics (Suzhou) Co. Ltd.268
已完成
1 期
A Phase I Study of CS1002 in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04338724CStone Pharmaceuticals6
终止
1 期
Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH DeficiencyPhenylketonuriasPAH DeficiencyPhenylketonuriaNCT05222178Homology Medicines, Inc3